OpenLegislation

The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017

S.I. 2017/631 · Made 6 May 2017

Original text. legislation.gov.uk does not revise statutory instruments, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Dangerous Drugs, England And Wales

Dangerous Drugs, Scotland

Made 6th May 2017

Coming into force 31st May 2017

To be laid before Parliament 13th June 2017

The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971f1.

In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

Annotations to the whole text

Footnotes

f1

1971 c. 38; section 22 was amended by section 177(1) of, and paragraph 12 of Schedule 4, to the Customs and Excise Management Act 1979 (c. 2); other amendments have been made to sections 7, 10 and 31 that are not relevant to these Regulations.

Contents

  1. 1Citation, commencement and extent
  2. 2Amendment of the Misuse of Drugs Regulations 2001
  3. 3Amendment of the Misuse of Drugs Regulations 2001
  4. Signature
  5. Explanatory note

1Citation, commencement and extent

(1)

These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.

(2)

These Regulations extend to England and Wales and Scotland.

2Amendment of the Misuse of Drugs Regulations 2001

The Misuse of Drugs Regulations 2001f1 are amended as follows.

3Amendment of the Misuse of Drugs Regulations 2001

In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16 , 18, 19, 20, 23, 26 and 27)—

(a)

before “Bufotenine” insert—

  • “Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

  • N-Benzyl-ethylphenidate

  • Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;

(b)

after “Cathinone” insert—

  • “4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(c)

after “Concentrate of poppy-straw” insert—

  • “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • 3,4-Dichloroethylphenidate

  • 3,4-Dichloromethylphenidate (3,4-DCMP)

  • Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(d)

after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—

  • “Ethylnaphthidate

  • Ethylphenidate”;

(e)

after “Eticyclidine” insert—

  • “Etizolam”;

(f)

after “Etryptamine” insert—

  • “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

  • 4-Fluoroethylphenidate

  • 4-Fluoromethylphenidate

  • Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(g)

after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol” insert—

  • “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

  • Isopropylphenidate (IPP or IPPD)”;

(h)

after “Lysergide and other N-alkyl derivatives of lysergamide” insert—

  • “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;

(i)

after “Methcathinone” insert—

  • “4-Methylmethylphenidate

  • Methylmorphenate

  • Methylnaphthidate (HDMP-28)

  • Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

  • Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)

  • Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

  • Propylphenidate”;

(j)

after “Psilocin” insert—

  • “Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;

(k)

after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—

  • “3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”.

Signature

Sarah Newton

Parliamentary Under Secretary of State

Home Office

6th May 2017

Explanatory note

(This note is not part of the Regulations)

These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the Regulations”). The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.

Regulation 3 adds a synthetic opioid (known as U-47,700), several methylphenidate related materials and a number of designer benzodiazepines to Schedule 1 to the Regulations. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.

An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.